Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful.
Modern Meadow is a purpose-driven company positioned at the intersection of material science and biology with a mission to be a catalyst for real-world impact on people and the planet. Modern Meadow’s proprietary Bio-Alloy™ and Bio-F@rm™ technology application platforms harness the unique properties of tuned proteins to sustainably move the world away from petrochemical and animal-derived inputs without compromising on performance. These innovations can drop into any existing infrastructures for immediate scalable adoption in the materials, beauty, and other industries. Our close relationship with development partners and production facilities allows companies partnering with Modern Meadow to feel confident knowing our products are 100% traceable from Lab-to-Brand™.
A-Alpha Bio is a provider of cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio utilizes its proprietary AlphaSeq technology to map protein-protein interactions at a high scale and resolution. This technology can identify and quantify interactions between thousands of protein pairs simultaneously. By providing detailed maps of protein interactions, A-Alpha Bio aids in the identification of potential drug targets and the understanding of disease mechanisms. This can significantly streamline the process of discovering new therapeutics. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.
Zymochem provides a carbon-efficient bio-manufacturing platform that converts renewable feedstocks into bio-based materials without compromising price, performance, scale, or sustainability while minimizing CO2 loss during production. It also accelerates a real-zero economy by relieving carbon emissions in product development, use, and end-of-life.
CellChorus provides a comprehensive, dynamic analysis of single cells for biopharmaceutical companies. The company’s TIMING™ platform applies visual AI to evaluate cell activation, killing and movement as a function of time in order to maximize our understanding of the cellular function, state, and phenotype of immuno-oncology and other therapies.
Appia Bio is a biotechnology company that focuses on the research and development of off-the-shelf allogeneic cell therapies. It works on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
